Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its Deramiocel cell therapy between December 2025 and July 2026. The FDA's briefing documents criticized the company's statistical analysis methods, and an advisory panel voted 9-3 against the therapy's efficacy, causing the stock to plummet 62% on July 27, 2026. Investors who purchased shares during the class period are urged to file claims by September 28, 2026.

09/14/2026, 12:55 PM • GlobeNewswire

מועד אחרון לתביעה ייצוגית נגד CAPRICOR: רוזן, יועץ משפטי מוביל למשקיעים, קורא למשקיעי חברת Capricor Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה ייצוגית בניירות הערך – CAPR

Rosen Law Firm reminds investors in Capricor Therapeutics, Inc. (CAPR) of the September 28, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Capricor made false statements regarding changes to statistical analysis plans for its Deramiocel treatment without FDA approval, creating substantial risk of regulatory rejection and misleading investors about the company's prospects.

09/13/2026, 10:20 AM • GlobeNewswire

CAPRICOR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Capricor Therapeutics, which allegedly made false statements about its Deramiocel cell therapy by failing to disclose changes to statistical analysis plans and lack of FDA agreement before resubmitting its Biologics License Application. The lead plaintiff deadline is September 28, 2026. Additional lawsuits involve Innventure, Inc. and Planet Fitness, Inc.

09/13/2026, 10:20 AM • GlobeNewswire

CAPRICOR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm alerts investors in Capricor Therapeutics (CAPR) who purchased securities between December 17, 2025 and July 26, 2026 of an important September 28, 2026 deadline to join a securities class action. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks that were not properly disclosed to investors.

09/10/2026, 5:54 PM • GlobeNewswire

CAPR Legal Notice: BFA Law Notifies Capricor Therapeutics Investors that Lost Money of the Imminent September 28 Securities Fraud Class Action Deadline

Capricor Therapeutics faces a securities fraud class action lawsuit alleging the company made false statements about its lead product Deramiocel and misrepresented clinical data integrity in its FDA Biologics License Application. The lawsuit was triggered by a 64.5% stock drop on July 27, 2026, following FDA briefing documents that raised concerns about post-hoc changes to the statistical analysis plan. Investors have until September 28, 2026 to request lead plaintiff status.

09/09/2026, 6:36 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

09/08/2026, 4:58 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPR

Pomerantz LLP has filed a class action lawsuit against Capricor Therapeutics for alleged securities fraud related to its Deramiocel BLA submission to the FDA. The FDA's briefing documents revealed that Capricor altered its statistical analysis plan one day before data unblinding without FDA approval, leading the FDA to deem the analyses as 'post-hoc and exploratory.' Following the FDA's negative assessment on July 27, 2026, Capricor's stock plummeted 64%, and an advisory committee voted 9-3 against the drug's efficacy on July 30, 2026, causing an additional 36% stock decline.

09/08/2026, 4:57 PM • GlobeNewswire

CAPR DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm announces securities class action lawsuits against multiple companies, including Capricor Therapeutics, for allegedly making materially false statements. Capricor is accused of failing to disclose changes to statistical analysis plans for its Deramiocel cell therapy and FDA concerns regarding regulatory approval for Duchenne muscular dystrophy treatment. Investors with losses exceeding $100K are encouraged to join the class action before the September 28, 2026 deadline.

09/07/2026, 7:59 PM • GlobeNewswire

RXT FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Rackspace Technology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RXT

Rosen Law Firm has filed securities class action lawsuits against Rackspace Technology, Capricor Therapeutics, and Smartsheet Inc., alleging that company defendants made false or misleading statements regarding their business operations and financial prospects. Investors with losses exceeding $100,000 are encouraged to join the class actions before upcoming deadlines.

09/07/2026, 7:07 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Datavault AI Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DVLT

Rosen Law Firm is notifying investors about securities class action lawsuits filed against Datavault AI Inc., Capricor Therapeutics Inc., and Smartsheet Inc. Investors who purchased securities during specified class periods are encouraged to seek counsel before important deadlines. The lawsuits allege material misstatements and omissions regarding business operations and partnerships.

09/07/2026, 7:02 PM • GlobeNewswire

CAPR FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm is reminding investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who purchased securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy.

09/04/2026, 5:35 PM • GlobeNewswire

CAPR 最終截止日期：全球投資者法律顧問 ROSEN 鼓勵蒙受損失超過 10 萬美元的 Capricor Therapeutics, Inc. 投資者在對 CAPR 提出證券集體訴訟的重要截止日期前聘請律師

Rosen Law Firm reminds investors who purchased Capricor Therapeutics securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 deadline to become lead plaintiffs in a securities class action. The lawsuit alleges the company made false statements regarding modifications to statistical analysis plans for its Deramiocel cell therapy and FDA approval risks for treating Duchenne muscular dystrophy.

09/04/2026, 5:35 PM • GlobeNewswire

Build-A-Bear Investor News: If You Have Suffered Losses in Build-A-Bear Workshop, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm has announced investigations into potential securities claims against Build-A-Bear Workshop, Inc. and Capricor Therapeutics, Inc., alleging that both companies may have issued materially misleading business information to investors. The firm is preparing class actions to recover investor losses through contingency fee arrangements.

09/04/2026, 5:09 PM • GlobeNewswire

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for allegedly making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of FDA rejection. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.

09/03/2026, 10:48 AM • GlobeNewswire

Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline

Capricor Therapeutics faces a securities class action lawsuit alleging material misstatements regarding clinical trial data for its lead drug deramiocel. The FDA extended the review period for the drug's Biologics License Application to November 2026 after revealing the company made undisclosed modifications to its statistical analysis plan. The stock crashed 64% on July 27, 2026, when FDA briefing documents revealed the HOPE-3 study failed to meet pre-specified primary endpoints. Investors who purchased shares between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

09/02/2026, 6:59 PM • GlobeNewswire